WANTED: A FEW GOOD ASSAYS

Pin It

There has been much concern over the fate of medication development for mental disorders. Some have complained that there are no truly novel medications coming from the pharmaceutical companies in the past three decades. Others have worried that the recent departure of pharmaceutical companies from psychiatric medication development presages a long draught with no new medical treatments likely. Meanwhile results from the large NIMH-funded comparative effectiveness trials, like CATIE and STAR*D, remind us of the need for a new generation of medications. At NIMH, we have been discussing how we might catalyze the next generation of drug discovery and development. One way, we believe, is by creating assays to probe new molecular targets relevant to mental disorders and to screen for new medications. Judging from recent progress, this approach looks hopeful………

Thomas R. Insel, M.D.
NIMH Director
NIMH DIRECTOR BLOG
http://www.nimh.nih.gov/about/director/index.shtml#p118147


Disclaimer
: Neither SARDAA nor SA, assume any legal liability, responsibility nor does inclusion of articles or comments constitute or imply its endorsement, recommendation, or favoring for the accuracy, completeness, or usefulness of any information, product or process disclosed in the blog.

Speak Your Mind

*